Head to Head Review: Precision Therapeutics (NASDAQ:POAI) & Histogenics (NASDAQ:HSGX)

Precision Therapeutics (NASDAQ:POAI) and Histogenics (NASDAQ:HSGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Institutional and Insider Ownership

10.9% of Precision Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Histogenics shares are held by institutional investors. 13.9% of Precision Therapeutics shares are held by insiders. Comparatively, 19.7% of Histogenics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Precision Therapeutics and Histogenics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Precision Therapeutics $1.41 million 7.97 -$10.09 million N/A N/A
Histogenics N/A N/A -$8.64 million ($0.79) -0.48

Histogenics has lower revenue, but higher earnings than Precision Therapeutics.

Profitability

This table compares Precision Therapeutics and Histogenics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Precision Therapeutics -674.64% -86.24% -50.92%
Histogenics N/A -34.96% 18.40%

Risk and Volatility

Precision Therapeutics has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Histogenics has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Precision Therapeutics and Histogenics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precision Therapeutics 0 0 0 0 N/A
Histogenics 0 1 0 0 2.00

Summary

Histogenics beats Precision Therapeutics on 7 of the 8 factors compared between the two stocks.

Precision Therapeutics Company Profile

Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.

Histogenics Company Profile

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.